WilmerHale represented the underwriters in the public offering of 10,000,000 shares of common stock of Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing small molecule drugs discovered through the application of its deuterated chemical entity platform. The offering priced on June 1, 2022 at $4.75 per share and closed on June 6, 2022, resulting in gross proceeds to Concert from the follow-on offering of $47.5 million, before deducting underwriting discounts, commissions and offering expenses. Concert also concurrently announced the receipt of $18.9 million upon the exercise of tranche 1 warrants to purchase 3,981 shares of Series X1 Preferred Stock issued to certain investors in November 2021.

The WilmerHale team advising the underwriters consisted of Lisa Firenze, Erin Garrity and Kevin Cheng, with assistance from Bruce Manheim and Colleen Superko.